Pomalidomide suppresses cerulein-induced acute pancreatitis in mice

Journal of Gastroenterology

Volumn 46, Issue 6, 2011, Pages 822-833

  Tsai, Ming Jen ^a,b   Chen, Chinpiao ^c   Chen, Sung Ho ^a   Huang, Yen Ta ^a,b   Chiu, Ted H ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c NATIONAL DONG HWA UNIVERSITY   (Taiwan)

Author keywords

CC 4047; Cerulein; Cytokines; Pancreatitis; Pomalidomide

Indexed keywords

AMYLASE; CERULETIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; POMALIDOMIDE; TRIACYLGLYCEROL LIPASE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PANCREATITIS; AMYLASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERAPY EFFECT; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ACUTE DISEASE; ADMINISTRATION, ORAL; AMYLASES; ANIMALS; CAERULEIN; DISEASE MODELS, ANIMAL; IMMUNOLOGIC FACTORS; LIPASE; MALE; MICE; MICE, INBRED C57BL; PANCREATITIS; SEVERITY OF ILLNESS INDEX; THALIDOMIDE;

EID: 79960250077     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0394-x     Document Type: Article

References (36)

1. Russo MW, Wei JT, Thiny MT, Gangarosa LM, Brown A, Ringel Y, et al. Digestive and liver diseases statistics, 2004. Gastroenterology. 2004;126:1448-53. (Pubitemid 38552807)
2. Sekimoto M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, et al. JPN Guidelines for the management of acute pancreatitis: epidemiology, etiology, natural history, and outcome predictors in acute pancreatitis. J Hepatobiliary Pancreat Surg. 2006;13:10-24. (Pubitemid 43193670)
3. Pezzilli R. Pharmacotherapy for acute pancreatitis. Expert Opin Pharmacother. 2009;10:2999-3014.
4. Algul H, Tando Y, Schneider G, Weidenbach H, Adler G, Schmid RM. Acute experimental pancreatitis and NF-kappaB/Rel activation. Pancreatology. 2002;2:503-9. (Pubitemid 35365338)
5. Granger J, Remick D. Acute pancreatitis: models, markers, and mediators. Shock. 2005;24(Suppl 1):45-51.
6. Malleo G, Mazzon E, Siriwardena AK, Cuzzocrea S. Role of tumor necrosis factor-alpha in acute pancreatitis: from biological basis to clinical evidence. Shock. 2007;28:130-40. (Pubitemid 47220822)
7. Mcbride WG. Thalidomide and congenital abnormalities. Lancet. 1961;278:1358.
8. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther. 1965;6:303-6.
9. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177:1675-80. (Pubitemid 23146134)
10. Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O. Treatment of refractory rheumatoid arthritis-the thalidomide experience. J Rheumatol. 1989;16:158-63. (Pubitemid 19085218)
11. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med. 1992;326:1055-8.
12. Wettstein AR, Meagher AP. Thalidomide in Crohn's disease. Lancet. 1997;350:1445-6. (Pubitemid 28036869)
13. Muller GW, Corral LG, Shire MG, Wang H, Moreira A, Kaplan G, et al. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem. 1996;39:3238-40. (Pubitemid 26322847)
14. Muller GW, Chen R, Huang SY, Corral LG, Wong LM, Patterson RT, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett. 1999;9: 1625-30. (Pubitemid 29274209)
15. Marriott JB, Muller G, Stirling D, Dalgleish AG. Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opin Biol Ther. 2001;1:675-82. (Pubitemid 33769078)
16. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163:380-6. (Pubitemid 29295864)
17. Payvandi F, Wu L, Haley M, Schafer PH, Zhang LH, Chen RS, et al. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol. 2004;230:81-8. (Pubitemid 39626649)
18. Demols A, Le Moine O, Desalle F, Quertinmont E, Van Laethem JL, Deviere J. CD4(?)T cells play an important role in acute experimental pancreatitis in mice. Gastroenterology. 2000;118: 582-90. (Pubitemid 30140857)
19. Muller GW, Stirling DI, Chen R. Methods of reducing TNF-a levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoand 1,3-dioxosioindolines. Chem Abstr. 1997;127:86110. US Patent 5635517, 1997.
20. Cuzzocrea S, Mazzon E, Dugo L, Serraino I, Centorrino T, Ciccolo A, et al. Inducible nitric oxide synthase-deficient mice exhibit resistance to the acute pancreatitis induced by cerulein. Shock. 2002;17:416-22.
21. Escobar J, Pereda J, Arduini A, Sandoval J, Sabater L, Aparisi L, et al. Cross-talk between oxidative stress and pro-inflammatory cytokines in acute pancreatitis: a key role for protein phosphatases. Curr Pharm Des. 2009;15:3027-42.
22. Sateesh J, Bhardwaj P, Singh N, Saraya A. Effect of antioxidant therapy on hospital stay and complications in patients with early acute pancreatitis: a randomised controlled trial. Trop Gastroenterol. 2009;30:201-6.
23. Que RS, Cao LP, Ding GP, Hu JA, Mao KJ, Wang GF. Correlation of nitric oxide and other free radicals with the severity of acute pancreatitis and complicated systemic inflammatory response syndrome. Pancreas. 2010;39:536-40.
24. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314-22. (Pubitemid 38525287)
25. Papachristou GI, Sass DA, Avula H, Lamb J, Lokshin A, Barmada MM, et al. Is the monocyte chemotactic protein-1-2518 G allele a risk factor for severe acute pancreatitis? Clin Gastroenterol Hepatol. 2005;3:475-81. (Pubitemid 40616913)
26. Regner S, Appelros S, Hjalmarsson C, Manjer J, Sadic J, Borgstrom A. Monocyte chemoattractant protein 1, active carboxypeptidase B and CAPAP at hospital admission are predictive markers for severe acute pancreatitis. Pancreatology. 2008;8: 42-9. (Pubitemid 351587251)
27. Bhatia M, Ramnath RD, Chevali L, Guglielmotti A. Treatment with bindarit, a blocker of MCP-1 synthesis, protects mice against acute pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2005;288:G1259-65. (Pubitemid 40741080)
28. Ishibashi T, Zhao H, Kawabe K, Oono T, Egashira K, Suzuki K, et al. Blocking of monocyte chemoattractant protein-1 (MCP-1) activity attenuates the severity of acute pancreatitis in rats. J Gastroenterol. 2008;43:79-85. (Pubitemid 351324990)
29. Cuzzocrea S, Genovese T, Mazzon E, Di Paola R, Muia C, Britti D, et al. Reduction in the development of cerulein-induced acute pancreatitis by treatment with M40401, a new selective superoxide dismutase mimetic. Shock. 2004;22:254-61. (Pubitemid 39468991)
30. Virlos I, Mazzon E, Serraino I, Di Paola R, Genovese T, Britti D, et al. Pyrrolidine dithiocarbamate reduces the severity of cerulein- induced murine acute pancreatitis. Shock. 2003;20:544-50.
31. Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol. 2002;130:75-84.
32. Payvandi F, Wu L, Naziruddin SD, Haley M, Parton A, Schafer PH, et al. Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT. J Interferon Cytokine Res. 2005;25:604-16. (Pubitemid 41507816)
33. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, et al. Immunomodulatory drugs stimulate natural killercell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008;140:36-45. (Pubitemid 350233246)
34. Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004;22:3269-76. (Pubitemid 41103682)
35. Liu WM, Henry JY, Meyer B, Bartlett JB, Dalgleish AG, Galustian C. Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer. 2009;101:803-12.
36. Shalapour S, Zelmer A, Pfau M, Moderegger E, Costa- Blechschmidt C, van Landeghem FK, et al. The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo. Clin Cancer Res. 2006;12:5526-32. (Pubitemid 44497270)